La Jolla Pharmaceutical Company Announces $100 Million Public Offering of Common Stock
Cowen is acting as the sole book-running manager for the offering.
La Jolla intends to use the proceeds from the proposed sale of its shares of common stock for general corporate purposes, which include, but are not limited to, the continued commercialization of GIAPREZATM (angiotensin II), funding its ongoing and future clinical trials of LJPC-401, preclinical development work and other administrative expenses.
The offering is being made pursuant to a registration statement that was filed with the
Forward Looking Statement Safe Harbor
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to expectations regarding the closing of the above referenced securities offering. These statements are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors. La Jolla cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties and other factors are described in greater detail in La Jolla’s filings with the
Director, Investor Relations & Human Resources
Phone: (858) 207-4264 Ext: 1135
Chief Financial Officer
Phone: (858) 207-4264 Ext: 1040